Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Colorectal cancer (CRC) remains a significant global health challenge, causing numerous cancer deaths worldwide.
• Recombinant DNA technology has revolutionized CRC treatment, leading to the development of effective therapeutic antibodies.
• Numerous novel therapeutic targets for CRC are continuously being identified.

Purpose of the Study:

• To review the physiological and pathophysiological roles of known and emerging therapeutic targets in CRC.
• To elucidate the signaling mechanisms of these CRC targets.
• To discuss the clinical development and FDA-approved status of monoclonal antibodies for CRC therapy.

Main Methods:

• Literature review of current research on CRC therapeutic targets.
• Analysis of signaling pathways involving growth factors, receptors, and immune checkpoint proteins in CRC.
• Examination of clinical trial data and FDA approvals for CRC-targeting monoclonal antibodies.

Main Results:

• Identified key growth factors, their receptors, and immune checkpoint proteins as critical targets in CRC.
• Detailed the roles and signaling pathways of these targets in CRC progression.
• Summarized the current landscape of monoclonal antibodies in clinical trials and those approved for CRC treatment.

Conclusions:

• Therapeutic antibodies represent a major class of drugs for colorectal cancer.
• Understanding target roles and signaling is crucial for developing effective antibody therapies.
• The review provides a comprehensive overview of antibody-based CRC treatments and their therapeutic potential.